Abstract
Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals. Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments. In particular, the interest in 18F-labeled proteins remains high for both diagnoses and therapy monitoring purposes. The development of labeling strategies for the synthesis of new 18F labeled protein is, however, not trivial. 18F-containing prosthetic groups are often required for protein labeling to obtain high yield under mild labeling conditions and keep the bioactive character of the proteins. This review highlights key aspects of protein 18F-labeling method and discussed representative examples including 18F-labeled human serum albumin, 18F-labeled Annexin V, 18F-labeled HER2 affibody, and 18F-labeled low density lipoprotein.
Keywords: 18F, Amine reactive prosthetic groups, Carboxylic acid reactive prosthetic groups, Thiol-reactive prosthetic groups, 18F-Labeled proteins, Positron emission tomography (PET)
Current Pharmaceutical Biotechnology
Title: 18F-Labeled Proteins
Volume: 11 Issue: 6
Author(s): Zhanhong Wu and Fouad Kandeel
Affiliation:
Keywords: 18F, Amine reactive prosthetic groups, Carboxylic acid reactive prosthetic groups, Thiol-reactive prosthetic groups, 18F-Labeled proteins, Positron emission tomography (PET)
Abstract: Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals. Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments. In particular, the interest in 18F-labeled proteins remains high for both diagnoses and therapy monitoring purposes. The development of labeling strategies for the synthesis of new 18F labeled protein is, however, not trivial. 18F-containing prosthetic groups are often required for protein labeling to obtain high yield under mild labeling conditions and keep the bioactive character of the proteins. This review highlights key aspects of protein 18F-labeling method and discussed representative examples including 18F-labeled human serum albumin, 18F-labeled Annexin V, 18F-labeled HER2 affibody, and 18F-labeled low density lipoprotein.
Export Options
About this article
Cite this article as:
Wu Zhanhong and Kandeel Fouad, 18F-Labeled Proteins, Current Pharmaceutical Biotechnology 2010; 11(6) . https://dx.doi.org/10.2174/138920110792246564
DOI https://dx.doi.org/10.2174/138920110792246564 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Synthesis and Biological Activity of New 4β-N-Heteroaryl Analogues of Podophyllotoxin
Letters in Drug Design & Discovery Development and Biocompatibility Analysis of NBD Peptide Sustained- Release Microsphere Scaffold Nanoparticle SP-Sr-CaS/NBD
Current Drug Delivery Anti-breast Cancer Potential of Natural and Synthetic Coumarin Derivatives
Current Topics in Medicinal Chemistry Interleukin-18: Biology and Role in the Immunotherapy of Cancer
Current Medicinal Chemistry Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Quantization of Angiogenesis and Image Analysis
Current Angiogenesis (Discontinued) Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Editorial: Plant Derived Secondary Metabolites as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas
Anti-Cancer Agents in Medicinal Chemistry Molecular Advances Toward the Understanding of the Patho-Biology of Idiopathic Myelofibrosis
Current Immunology Reviews (Discontinued) Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Local Drug Delivery Based Treatment Approaches for Effective Management of Periodontitis
Current Drug Therapy Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry